Briefly, activation of Wnt-β-catenin is associated with the expression of HCC stem cell markers such as CD133 and EpCAM, and reduced response to chemotherapeutic agents [138, 139]. This evidence concerns the gene EPCAM and hepatocellular carcinoma.